Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.
نویسندگان
چکیده
INTRODUCTION Oxaliplatin is a third-generation platinum compound with proven antitumor activity in the treatment of colorectal cancer. The occurrence of life-threating hemolitic uremic syndrome has been observed after oxaliplatin therapy. The kind of tumor and treatment modalities seem to influence the onset of hemolitic uremic syndrome. METHODS The clinical course of the case is reviewed and compared with reports of other similar cases in the literature. RESULTS We describe the development of hemolitic uremic syndrome as a result of prolonged oxaliplatin treatment of a colon cancer patient. CONCLUSIONS Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting.
منابع مشابه
Concurrent Atypical Hemolytic Uremic Syndrome and Autoimmune Hemolytic Anemia: a case report
Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening and scarce disorder characterized by acute renal failure and disease, non-immune microangiopathic hemolytic anemia and thrombocytopenia, leading to end-stage renal failure or death, and consequently maybe accompanying by extra renal manifestations. Case report: We reported aHUS accompanied by autoimmune hemolytic anemi...
متن کاملHemolytic uremic syndrome following the infusion of oxaliplatin: case report
BACKGROUND Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal cancer. A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported. We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin. CASE PRESENTATION A 52-year-old...
متن کاملRole of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
BACKGROUND The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes. One of the most promising agents is eculizumab, which is a monoclonal antibody directed against C5 complement protein. CASE PRESENTATION We reported the c...
متن کاملPlasma infusion therapy in atypical hemolytic uremic syndrome long term outcome.
We report 2 boys with atypical (diarrhea negative) hemolytic uremic syndrome requiring dialysis, who recovered complete renal functions after receiving fresh frozen plasma infusion therapy. One patient relapsed and required second course of plasma infusion therapy. After a prolonged follow up, both showed normal renal functions with mild residual hypertension.
متن کاملGemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Tumori
دوره 97 5 شماره
صفحات -
تاریخ انتشار 2011